studies

breast cancer - HER2-positive, antibody–drug conjugate vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDESTINY Breast03, 2022 0.55 [0.36; 0.85] EMILIA, 2012 0.68 [0.55; 0.85] 0.65[0.54; 0.79]DESTINY Breast03, 2022, EMILIA, 201220%991moderatenot evaluable deaths (OS) (extension)detailed resultsEMILIA, 2012 0.75 [0.64; 0.88] 0.75[0.64; 0.88]EMILIA, 201210%991NAnot evaluable progression or deaths (PFS)detailed resultsDESTINY Breast03, 2022 0.28 [0.22; 0.36] EMILIA, 2012 0.65 [0.55; 0.77] 0.43[0.19; 0.98]DESTINY Breast03, 2022, EMILIA, 2012296%991moderatenot evaluable objective responses (ORR)detailed resultsEMILIA, 2012 1.73 [1.29; 2.32] 1.73[1.29; 2.32]EMILIA, 201210%786NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-20 12:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1086,1460,1232,1395,1233,1100,1433,1248

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons